Cepharanthine Reverses Gefitinib Resistance in NSCLC by Concurrently Inhibiting AKT/P70S6K Survival Signaling and Activating STING-Mediated Immune Response
{{output}}
Acquired resistance to Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, remains a major therapeutic challenge in EGFR-mutant non-small cell lung cancer (NSCLC). Here, we report that cepharanthine (CEP), a natural bi... ...
